{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:51:00Z","timestamp":1740178260053,"version":"3.37.3"},"reference-count":14,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"DOI":"10.1182\/bloodadvances.2024013812","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:41:33Z","timestamp":1729006893000},"page":"5430-5432","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Too short or unnecessarily long: walking the fine line"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-9956","authenticated-orcid":false,"given":"Chiranjeevi","family":"Sainatham","sequence":"first","affiliation":[{"name":"1Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"2Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"20","key":"2024110821154602600_bib1","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"2024110821154602600_bib2","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2024110821154602600_bib3","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2024110821154602600_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024110821154602600_bib5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"20","key":"2024110821154602600_bib6","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T cell therapy: analysis of FDA adverse events reporting system (FAERS)","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2024110821154602600_bib7","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"20","key":"2024110821154602600_bib8","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2024110821154602600_bib9","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS)","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2024110821154602600_bib10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf"},{"issue":"10","key":"2024110821154602600_bib11","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/ refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"2024110821154602600_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jtct.2023.11.008","article-title":"Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Oluwole","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2024110821154602600_bib13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.19090","article-title":"Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages","volume":"203","author":"Ly","year":"2023","journal-title":"Br J Haematol"},{"key":"2024110821154602600_bib14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.012","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","author":"Wesson","year":"11  2024","journal-title":"Transplant Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5430\/2312386\/blooda_adv-2024-013812-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5430\/2312386\/blooda_adv-2024-013812-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T21:15:56Z","timestamp":1731100556000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/20\/5430\/518160\/Too-short-or-unnecessarily-long-walking-the-fine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":14,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013812","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}